Warfarin anticoagulation has been used extensively in adults. In children there has been limited use of this agent and we were unable to find published reports about dosage in this age group. Heparin has been used in children for disseminated intravascular coagulation, but its use under these circumstances is short lived and usually related to an acute episode. In recent years indications for long-term anticoagulation have become more common, e.g. idiopathic nonobstructive cardiomyopathy and in patients in whom cardiac valves have been replaced by prosthetic valves.
The most important problems in anticoagulation therapy of children are the choice of the anticoagulant, its efficiency, dosage, and possible complications secondary to children's routine activity. This paper reports the experience with the use of warfarin in children and adolescents. Material Crystalline sodium warfarin (Coumadin) was used in every case, with a dosage range of 0 * 31 -0 mg/kg. The total loading dose of 10-40 mg was followed by daily maintenance of 15-25% of loading dose (2 5-10 mg). The effects were assessed by daily prothrombin time. A prothrombin time of 1 5-2-5 times the control was considered to be therapeutic. Adjustment of the maintenance dose was made when necessary with changes of 1-0-2 0 mg daily or on alternate days.
Treatment was started on the second or third day after surgery or the estimated time of embolism. In the 4 patients with cerebral embolism treatment was begun after 3 to 4 weeks in order to avoid the possible danger of transforming a white into a red thrombus.
The first 15 patients were given empirical doses, and the remaining 4 patients (Cases 16 to 19) were given When stable therapeutic prothrombin time was reached and all the other clinical problems were resolved, the patients were discharged and followed up monthly by their physician or by our clinic.
Results
The Fig. shows prothrombin time 36 hours after a loading dose, against loading doses expressed in mg/kg body weight. The therapeutic prothrombin time was always achieved at about 36-48 hours and was obtained with a dosage of between 0 5 and 0 * 7 mg/kg. In 7 patients warfarin was discontinued because the prothrombin time had exceeded 30 seconds. Treatment was restarted with a lower loading dose. In 3 patients with a prothrombin time of 40 s, vitamin K was given. In another case, vitamin K was ineffective and prothrombin time was restored to normal by giving fresh plasma IV.
In the first 15 cases an average of four adjustments (range 3-7) were made in warfarin maintenance dosage before stabilization of the desired prothrombin time. The average time taken to reach this dosage was 20 days (range 8-70 days). Using the Fig. as 
Discussion
Anticoagulant treatment with warfarin sodium may be indicated to prevent thrombi occurring after a prosthetic valve insertion or in cases of idiopathic nonobstructive cardiomyopathy. In adults, extensive reviews of anticoagulation therapy with coumarin congeners have been published (Alexander, 1962; Aggeler and O'Reilly, 1966; O'Reilly and Aggeler, 1970; Wright, 1969; Wessler, 1974) since the successful treatment of pulmonary embolism in 1960 (Barritt and Jordan, 1960 However, we could find no references to long-term anticoagulation with such drugs in children.
In this study the only drug used for anticoagulation was warfarin and no attempt was made to compare its effect with other anticoagulants. Warfarin sodium is a water soluble derivative of coumaric acid. Absorbed completely in the small intestine, it is loosely bound to albumin and transported in the blood. It is degraded in the liver and its degradation products, also bound to albumin, are excreted in the urine. Warfarin competes with vitamin K, which is necessary for the synthesis of factors II, VII, IX, and X of the coagulation cascade. Acute administration of warfarin lowers these factors. Factor VII is the most sensitive of all (Coon and Willis, 1970; Deykin, 1970) . Different adult dosages have been advised by various authors. Most recommend a large enough sodium warfarin dose to prolong and maintain prothrombin time between 1 5 and 2 5 times the control (Deykin, 1970; Koch-Weser, 1974) . In this study the range appeared to be both safe and effective with the exception of one patient with haematuria. In this instance prothrombin time had to be restricted to two times the control.
A loading dose was given in all our cases because in the authors' experience therapeutic prothrombin time could never be achieved with maintenance doses only. This differs from other results (Deykin, 1970; O'Reilly and Aggeler, 1968) . It is evident from our experience and of others (Alexander, 1962; O'Reilly and Aggeler, 1970; Wessler, 1974; Coon and Willis, 1970 ) that the dose of warfarin must be adjusted individually and precautions taken to avoid overdosage. The present study suggests that therapeutic prothrombin time can be attained by a warfarin loading dose of 0 5-0 7 mg/kg. Overdosage in our experience caused no serious complications and excessively prolonged prothrombin time was easily corrected with vitamin K.
In the cases in which warfarin dosage was lowered or discontinued there was no rebound phenomenon. This is at variance with data from other sources (A. Starr and Edwards Laboratories, personal communications, 1972 
